Virax Biolabs Group Limited, an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced the appointment of Iain Miller, PhD as an Independent Director to its Board of Directors, effective 29 July 2025.
Health Technology Insights: MedComms Experts Acquires NexGen to Expand Healthcare Communications
Dr. Miller succeeds Yair Erez, who is stepping down from the Board to focus on other professional endeavours. The Company thanks Mr Erez for his valuable service and contributions.
Dr. Miller brings over 30 years of leadership experience across the diagnostics and MedTech sectors, having held senior positions at GE Healthcare, bioMérieux, and Massachusetts General Hospital. He has worked extensively across both the United Kingdom and United States markets and has founded and led four MedTech companies, including Presymptom Health, a UK Ministry of Defence spinout, where he served as Chief Executive Officer. Under his leadership, Presymptom Health developed InfectiClear, a novel diagnostic for infectious diseases.
Dr. Miller has also served on the UK’s NICE Technology Appraisal Committee and contributed to innovation programmes at NHS England and the Medicines and Healthcare products Regulatory Agency . He holds a PhD in BioEngineering from the University of Strathclyde, an MBA from the University of Edinburgh, and a BSc in Physics & Electronics from the University of Glasgow. He has published extensively on diagnostic innovation. His commercial, technical, and regulatory expertise is expected to contribute meaningfully to Virax’s business strategy as the Company works to expand its immune profiling platform into new markets.
Health Technology Insights: AI and 3D Dental Imaging Rolled Out to 1,000+ Clinics
“We are pleased to welcome Iain Miller, PhD to the Virax Board during this important phase of development,” said James Foster, Chief Executive Officer of Virax Biolabs. “His leadership across private and public sector organisations, combined with deep diagnostics expertise and international experience, will be instrumental as we work to advance our immune profiling platform — building on our initial Research-Use-Only (RUO) product rollout and progressing toward IVD development, regulatory engagement, and future market entry.”
Dr. Miller commented: “I am excited to join the Board of Virax Biolabs at a time of strategic focus and momentum. The Company’s immune profiling platform presents a compelling opportunity to enhance how chronic and post-viral conditions are monitored. I look forward to supporting the team in realising this vision.”
Health Technology Insights: Clearwater Boosts Cyber Defense in Healthcare with Google Cloud Intel
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source- PR Newswire
